You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study
|
|---|---|
| Published in |
BMC Cancer, August 2015
|
| DOI | 10.1186/s12885-015-1597-y |
| Pubmed ID | |
| Authors |
Marline G. Harmsen, Marieke Arts-de Jong, Nicoline Hoogerbrugge, Angela H. E. M. Maas, Judith B. Prins, Johan Bulten, Steven Teerenstra, Eddy M. M. Adang, Jurgen M. J. Piek, Helena C van Doorn, Marc van Beurden, Marian J. E. Mourits, Ronald P. Zweemer, Katja N. Gaarenstroom, Brigitte F. M. Slangen, M. Caroline Vos, Luc R. C. W. van Lonkhuijzen, Leon F. A. G. Massuger, Rosella P. M. G. Hermens, Joanne A. de Hullu |
| Abstract |
Risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 is currently recommended to BRCA1/2 mutation carriers. This procedure decreases the elevated ovarian cancer risk by 80-96 % but it initiates premature menopause as well. The latter is associated with short-term and long-term morbidity, potentially affecting quality of life (QoL). Based on recent insights into the Fallopian tube as possible site of origin of serous ovarian carcinomas, an alternative preventive strategy has been put forward: early risk-reducing salpingectomy (RRS) and delayed oophorectomy (RRO). However, efficacy and safety of this alternative strategy have to be investigated. A multicentre non-randomised trial in 11 Dutch centres for hereditary cancer will be conducted. Eligible patients are premenopausal BRCA1/2 mutation carriers after completing childbearing without (a history of) ovarian carcinoma. Participants choose between standard RRSO at age 35-40 (BRCA1) or 40-45 (BRCA2) and the alternative strategy (RRS upon completion of childbearing and RRO at age 40-45 (BRCA1) or 45-50 (BRCA2)). Women who opt for RRS but do not want to postpone RRO beyond the currently recommended age are included as well. Primary outcome measure is menopause-related QoL. Secondary outcome measures are ovarian/breast cancer incidence, surgery-related morbidity, histopathology, cardiovascular risk factors and diseases, and cost-effectiveness. Mixed model data analysis will be performed. The exact role of the Fallopian tube in ovarian carcinogenesis is still unclear. It is not expected that further fundamental research will elucidate this role in the near future. Therefore, this clinical trial is essential to investigate RRS with delayed RRO as alternative risk-reducing strategy in order to improve QoL. ClinicalTrials.gov ( NCT02321228 ). |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 38% |
| Canada | 1 | 13% |
| Unknown | 4 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 153 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 153 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 21 | 14% |
| Student > Master | 18 | 12% |
| Student > Bachelor | 17 | 11% |
| Researcher | 12 | 8% |
| Student > Postgraduate | 9 | 6% |
| Other | 27 | 18% |
| Unknown | 49 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 59 | 39% |
| Nursing and Health Professions | 9 | 6% |
| Psychology | 9 | 6% |
| Biochemistry, Genetics and Molecular Biology | 5 | 3% |
| Economics, Econometrics and Finance | 2 | 1% |
| Other | 12 | 8% |
| Unknown | 57 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2015.
All research outputs
#6,290,058
of 22,824,164 outputs
Outputs from BMC Cancer
#1,569
of 8,302 outputs
Outputs of similar age
#73,637
of 266,176 outputs
Outputs of similar age from BMC Cancer
#22
of 139 outputs
Altmetric has tracked 22,824,164 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 8,302 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,176 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 139 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.